阿奇霉素+转移因子口服溶液对支原体肺炎患儿临床症状及肺功能的影响(1)
【摘要】 目的：探討支原体肺炎患儿应用阿奇霉素与转移因子口服溶液联合治疗对其临床症状以及肺功能的影响情况。方法：选取本院2016年12月-2018年3月收治的支原体肺炎患儿100例作为研究对象，按照随机数字表法将其分为对照组和观察组，各50例。对照组给予阿奇霉素治疗，观察组给予阿奇霉素与转移因子口服溶液联合治疗，比较两组治疗前后的肺功能改善、炎症改善及临床症状改善情况。结果：治疗后，两组肺功能指标水平与治疗前比较均明显升高，且观察组PEF、MMF以及FVC指标水平均明显高于对照组，差异均有统计学意义(P<0.05)。治疗后，两组炎症改善情况与治疗前比较均明显降低，且观察组TNF-α、IL-8、IL-6及IL-1β水平均明显低于对照组，差异均有统计学意义(P<0.05)。观察组的肺部体征、咳嗽及发热消失时间均明显短于对照组，差异均有统计学意义(P<0.05)。结论：对于支原体肺炎患儿，采用阿奇霉素与转移因子口服溶液联合治疗可有效改善各临床症状，提高肺功能，值得广泛推广并应用于临床。
【关键词】 阿奇霉素; 转移因子口服溶液; 支原体肺炎患儿; 肺功能
【Abstract】 Objective：To explore the effect of Azithromycin and Transfer Factor Oral Solution on clinical symptoms and pulmonary function in children with mycoplasma pneumonia.Method：A total of 100 children with mycoplasma pneumonia admitted in our hospital from December 2016 to March 2018 were selected as the research objects.According to the random number table method，they were divided into control group and observation group，50 cases in each group.The control group was treated with Azithromycin，the observation group was treated with Azithromycin and Transfer Factor Oral Solution.The improvement of pulmonary function，inflammation before and after treatment and clinical symptoms between two groups were compared.Result：After treatment，the levels of pulmonary function indexes in two groups were significantly higher than those before treatment，and the levels of PEF，MMF and FVC in the observation group were significantly higher than those in the control group，the differences were statistically significant(P<0.05).After treatment，the improvement of inflammation in two groups were significantly lower than those before treatment，and the levels of TNF-a，IL-8，IL-6 and IL-1β in the observation group were significantly lower than those in the control group，the differences were statistically significant(P<0.05).The disappearance time of pulmonary signs，cough and fever in the observation group were significantly shorter than those in the control group，the the differences were statistically significant(P<0.05).Conclusion：For children with mycoplasma pneumonia，Azithromycin and Transfer Factor Oral Solution combination therapy can effectively improve the clinical symptoms and increase pulmonary function and is worthy of wide promotion and clinical application.
【Key words】 Azithromycin; Transfer Factor Oral Solution; Children with mycoplasma pneumonia; Pulmonary function
First-author’s address：Jingmen Duodao People’s Hospital，Jingmen 448000，China, http://www.100md.com(朱亚君)
【关键词】 阿奇霉素; 转移因子口服溶液; 支原体肺炎患儿; 肺功能
【Abstract】 Objective：To explore the effect of Azithromycin and Transfer Factor Oral Solution on clinical symptoms and pulmonary function in children with mycoplasma pneumonia.Method：A total of 100 children with mycoplasma pneumonia admitted in our hospital from December 2016 to March 2018 were selected as the research objects.According to the random number table method，they were divided into control group and observation group，50 cases in each group.The control group was treated with Azithromycin，the observation group was treated with Azithromycin and Transfer Factor Oral Solution.The improvement of pulmonary function，inflammation before and after treatment and clinical symptoms between two groups were compared.Result：After treatment，the levels of pulmonary function indexes in two groups were significantly higher than those before treatment，and the levels of PEF，MMF and FVC in the observation group were significantly higher than those in the control group，the differences were statistically significant(P<0.05).After treatment，the improvement of inflammation in two groups were significantly lower than those before treatment，and the levels of TNF-a，IL-8，IL-6 and IL-1β in the observation group were significantly lower than those in the control group，the differences were statistically significant(P<0.05).The disappearance time of pulmonary signs，cough and fever in the observation group were significantly shorter than those in the control group，the the differences were statistically significant(P<0.05).Conclusion：For children with mycoplasma pneumonia，Azithromycin and Transfer Factor Oral Solution combination therapy can effectively improve the clinical symptoms and increase pulmonary function and is worthy of wide promotion and clinical application.
【Key words】 Azithromycin; Transfer Factor Oral Solution; Children with mycoplasma pneumonia; Pulmonary function
First-author’s address：Jingmen Duodao People’s Hospital，Jingmen 448000，China, http://www.100md.com(朱亚君)